Gilead Sciences Inc (GILD) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Total Cash From Operating Activities Chart for Gilead Sciences Inc
Gilead Sciences Inc (GILD) operating cash flow for FY2025 was USD 10.0B, a -7.5% change from FY2024. Gilead Sciences Inc's operating cash flow moved from USD -2.4M in 1990 to USD 10.0B in 2025 over 35 years. Operating cash flow compound annual growth rate: 5-year CAGR of 4.2%, 10-year CAGR of -7.2%, 20-year CAGR of 14.2%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $162.47B
- Implied Share Price
- $130.86
- Enterprise Value
- $182.45B
- Revenue (TTM)
- $30.46B
- EBITDA
- $15.24B
- Profit Margin
- -10.64%
- Trailing P/E
- —
- Forward P/E
- 15.22
- Price/Book (MRQ)
- 14.30
- Price/Sales (TTM)
- 5.33
- EV/EBITDA
- 12.25
- EV/Revenue
- 5.99
- Dividend Yield
- 2.44%
- Book Value
- $9.46
- Free Cash Flow (FY2025)
- $9.46B
- Free Cash Flow Yield
- 5.82%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.